The use of interferon alfa in the treatment of metastatic cutaneous melanoma
Shepherd J, Milne R
Record ID 31999009320
English
Authors' objectives:
To summarise the effectiveness and cost effectiveness of the use of interferon alfa in the treatment of metastatic cutaneous melanoma.
Authors' recommendations:
There is good evidence from RCTs that adding interferon alfa to dacarbazine does not improve survival or tumour response for people with metastatic malignant melanoma. There is clear evidence that interferon alfa has unpleasant and sometimes serious adverse effects. Interferon alfa is an expensive drug and the committee concluded that there was no reason to use it in addition to dacarbazine in the routine care of people with metastatic malignant melanoma.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.wihrd.soton.ac.uk
Year Published:
1999
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Costs and Cost Analysis
- Interferon-alpha
- Melanoma
- Paraneoplastic Syndromes
- Skin Neoplasms
Contact
Organisation Name:
Wessex Institute for Health Research and Development
Contact Address:
Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright:
Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.